On June 18, Thermo Fisher Scientific declined 3.1% in regular trading, trading at $459.11/share, with turnover of $487 million.

On the news front, multiple institutional rating actions continue to pressure the stock. Piper Sandler initiated coverage with a Neutral rating and a $510 price target, while HSBC downgraded the stock from Buy to Hold, slashing its target price from $670 to $540. These cautious stances from major brokerages have sustained downward pressure on share performance. The current price remains well below the analyst consensus target of $602.50.

The broader Life Sciences Tools & Services sector is also under significant pressure. Among sector peers, IQVIA fell 4.48%, Adaptive Biotechnologies declined 4.06%, Danaher dropped 2.51%, Tempus AI slid 2.20%, and Waters lost 1.09%, reflecting a broad-based sector selloff amplifying the downside momentum.

Thermo Fisher Scientific, founded in 1956 and headquartered in Waltham, Massachusetts, is a global leader in scientific services, providing life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products through brands including Thermo Scientific, Applied Biosystems, and Invitrogen.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)